Combining the antigen-presenting cell activator eftilagimod alpha (Soluble Lag-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of Tacti-002 (Phase Ii)
Authors
Iams, W.Felip, E.
Majem, M.
Doger, B.
Clay, T.
Carcereny, E.
Bondarenko, I.
Peguero, J.
Cobo-Dols, M.
Forster, M.
Ursol, G.
Kalinka, E.
Ledo, G. G.
Martinez, L. V.
Krebs, Matthew G
Balea, B. C.
Kefas, J.
Mueller, C.
Brignone, C.
Triebel, F.
Affiliation
Vanderbilt Ingram Cancer Center, Nashville, TN,Issue Date
2022
Metadata
Show full item recordCitation
Iams W, Felip E, Majem M, Doger B, Clay T, Carcereny E, et al. Combining the Antigen-Presenting Cell Activator Eftilagimod Alpha (Soluble Lag-3) and Pembrolizumab: Efficacy Results from the 1st Line Non-Small Cell Lung Cancer Cohort of Tacti-002 (Phase Ii). Journal for immunotherapy of cancer. 2022 Nov;10:A1529-A. PubMed PMID: WOS:000919423401574.Journal
Journal for Immunotherapy of CancerDOI
10.1136/jitc-2022-SITC2022.1470Additional Links
https://dx.doi.org/10.1136/jitc-2022-SITC2022.1470Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/jitc-2022-SITC2022.1470